Related Experiment Videos
Treatment of murine angiosarcoma with etoposide, TNP-470 and prednisolone
1Department of Dermatology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, 228-8555, Kanagawa, Japan.
Abstract:
To develop effective therapies for angiosarcoma, we investigated the anti-tumor effects of etoposide (ETO), TNP-470 and prednisolone (PSL) using an established murine angiosarcoma cell line (ISOS-1). We examined the direct anti-tumor and anti-angiogenic effects of these drugs on ISOS-1 cells and normal murine microvascular endothelial cells (mECs) in vitro. Cell growth of ISOS-1 was inhibited significantly by ETO, moderately by TNP-470, and not at all by PSL (IC(50): 0.25 microg/ml, 10 microg/ml, >8000 microg/ml, respectively). One the other hand, cell growth of mECs was inhibited significantly by TNP-470, slightly by PSL, and negligibly by ETO (IC(50): 0.85 ng/ml, 0.7 microg/ml, 10 microg/ml, respectively). In an in vivo assay, tumor growth of ISOS-1 was significantly inhibited by more than 2.5 mg/kg of ETO dose-dependently, and by more than 30 mg/kg of TNP-470, and 100 mg/kg of PSL individually. Combination treatments of ETO+TNP-470 and TNP-470+PSL showed synergistic enhancement of inhibition (% control inhibition: ETO vs. TNP-470 vs. ETO+TNP-470: 55 versus 55 vs. 16%) (% control inhibition: TNP-470 vs. PSL vs. TNP-470+PSL: 41 vs. 86 vs. 21%). ETO+PSL combination treatment, however, failed to show significant enhancement of anti-tumor effects. In conclusion, our results indicated that TNP-470 may be a very effective drug for angiosarcoma treatment, especially in combination with ETO or PSL. We eagerly anticipate the use of TNP-470 in clinical treatment of angiosarcoma.
Insights
TNP-470 shows promise for angiosarcoma treatment, particularly when combined with etoposide (ETO) or prednisolone (PSL). This study investigated the anti-tumor and anti-angiogenic effects of these drugs in vitro and in vivo.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Angiosarcoma is a rare and aggressive cancer requiring novel therapeutic strategies.
- Etoposide (ETO), TNP-470, and prednisolone (PSL) are potential anti-cancer agents with varying mechanisms of action.
Purpose of the Study:
- To evaluate the anti-tumor and anti-angiogenic efficacy of ETO, TNP-470, and PSL against murine angiosarcoma (ISOS-1) cells.
- To assess the synergistic effects of drug combinations for potential angiosarcoma therapy.
Main Methods:
- In vitro studies assessed drug effects on ISOS-1 cell growth and normal murine microvascular endothelial cells (mECs).
- In vivo studies evaluated tumor growth inhibition in a murine angiosarcoma model using individual and combination drug treatments.
Main Results:
- ETO significantly inhibited ISOS-1 cell growth, while TNP-470 had moderate effects, and PSL had minimal impact in vitro.
- TNP-470 significantly inhibited mEC growth, indicating anti-angiogenic potential, whereas ETO and PSL had lesser effects.
- In vivo, ETO, TNP-470, and PSL demonstrated dose-dependent tumor growth inhibition.
- Combination of TNP-470 with ETO or PSL showed synergistic anti-tumor effects, significantly enhancing inhibition compared to individual treatments.
Conclusions:
- TNP-470 exhibits significant anti-tumor and anti-angiogenic activity against angiosarcoma.
- Combination therapy with TNP-470 and either ETO or PSL offers a promising synergistic approach for angiosarcoma treatment.
- Further clinical investigation of TNP-470 for angiosarcoma is warranted.